Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk.

Feldt-Rasmussen B, Lange M, Sulowicz W, Gafter U, Lai KN, Wiedemann J, Christiansen JS, El Nahas M

Journal of the American Society of Nephrology : JASN6 Jun 2007Cited by 77 (Europe PMC)

PMID17554147DOI10.1681/asn.2006111207PepBankPUB-17554147

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, pooled hGH groups increased lean body mass by 2.5 kg versus -0.4 kg with placebo (P < 0.001).
In plain wordsIn adults on hemodialysis, hGH increased lean body mass more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass change
Study
n = 139
Comparator
Placebo
Analysis
Primary
Outcome group
Body composition · Musculoskeletal
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Measurements
Lean body mass change
2.5 kg
pooled hGH groups, 95% CI 1.8 to 3.1
Lean body mass change
−0.4 kg
placebo, 95% CI -1.4 to 0.6
Source sentences
Summary
The study showed that hGH treatment increased LBM significantly at all dosage levels (2.5 kg [95% confidence interval 1.8 to 3.1] versus -0.4 kg [95% confidence interval -1.4 to 0.6]; P < 0.001 for pooled hGH groups versus placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414701
02HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, serum albumin tended to increase with hGH (P = 0.076).
In plain wordsIn adults on hemodialysis, serum albumin tended to increase with hGH compared with placebo, without statistical significance.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum albumin
Study
n = 139
Comparator
Placebo
Analysis
Primary
Outcome group
Body composition · Whole body
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum albumin tended to increase (P = 0.076), serum transferrin (P = 0.001) and serum HDL (P < 0.038) increased, and plasma homocysteine was reduced (P = 0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414702
03HumanRandomized controlled trialSafety outcome
In adults on hemodialysis, clinically relevant adverse events did not differ between treatment groups.
In plain wordsIn adults on hemodialysis, clinically relevant adverse events did not differ between hGH and placebo groups.
Peptide
HGH (somatotropin)
Outcome
No significant changeClinically relevant adverse events
Study
n = 139
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in clinically relevant adverse events between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414708
04HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, serum transferrin increased with hGH (P = 0.001).
In plain wordsIn adults on hemodialysis, hGH increased serum transferrin compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum transferrin
Study
n = 139
Comparator
Placebo
Outcome group
Body composition · Whole body
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum albumin tended to increase (P = 0.076), serum transferrin (P = 0.001) and serum HDL (P < 0.038) increased, and plasma homocysteine was reduced (P = 0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414703
05HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, serum HDL increased with hGH (P < 0.038).
In plain wordsIn adults on hemodialysis, hGH increased HDL cholesterol compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum HDL
Study
n = 139
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum albumin tended to increase (P = 0.076), serum transferrin (P = 0.001) and serum HDL (P < 0.038) increased, and plasma homocysteine was reduced (P = 0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414704
06HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, plasma homocysteine decreased with hGH (P = 0.029).
In plain wordsIn adults on hemodialysis, hGH reduced homocysteine compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreasePlasma homocysteine
Study
n = 139
Comparator
Placebo
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum albumin tended to increase (P = 0.076), serum transferrin (P = 0.001) and serum HDL (P < 0.038) increased, and plasma homocysteine was reduced (P = 0.029).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414705
07HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, TNF-alpha tended to decrease with hGH (P = 0.134).
In plain wordsIn adults on hemodialysis, TNF-alpha tended to decrease with hGH compared with placebo, without statistical significance.
Peptide
HGH (somatotropin)
Outcome
No significant changeTNF-alpha
Study
n = 139
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
TNF-alpha also tended to decrease with treatment (P = 0.134).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414706
08HumanRandomized controlled trialEfficacy outcome
In adults on hemodialysis, hGH improved the Role Physical SF-36 quality-of-life subscale (P = 0.042).
In plain wordsIn adults on hemodialysis, hGH improved the physical-role quality-of-life score compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseRole Physical SF-36 subscale
Study
n = 139
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
20, 35, or 50 microg/kg per d · 6 monthsAs given in this study (human).
Source sentences
Summary
An improvement in the Role Physical SF-36 quality-of-life subscale was observed (P = 0.042).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels < or =40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 microg/kg per d hGH.
Summary · context
Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored.
Report a problemFND-1755414707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00943995

Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis

Nationwide Children's Hospitaln = 3Jul 2010 to Aug 2012

Kidney Failure, Chronic · Renal Dialysis

Trial page ClinicalTrials.govUpdated 5 May 2015

CompletedPhase 2NCT00184652

Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

Novo Nordisk A/Sn = 140Apr 2003 to Sept 2005

Chronic Kidney Disease · End-Stage Renal Disease

Trial page ClinicalTrials.govUpdated 24 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.